Kaizen Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Kaizen Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$59K	Buy	610 +111	+22%	+$13.1K	0.04%	304
2018 Q3	$69K	Hold	499	–	–	0.04%	282
2018 Q2	$62K	Buy	499 +281	+129%	+$32.8K	0.03%	291
2018 Q1	$24K	Sell	218 -7,673	-97%	-$917K	0.02%	301
2017 Q4	$944K	Buy	+7,891	New	+$961K	0.56%	84

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kaizen Advisory's ALXN Position: Q4 2018 in Review

Kaizen Advisory increased its Alexion Pharmaceuticals (ALXN) stake by 22% in Q4 2018, buying an estimated $13.1K and bringing the position to 610 shares worth $59K. The position accounts for 0.04% of the portfolio, ranked #304.

Kaizen Advisory first reported a position in ALXN in Q4 2017 and has held it in 5 quarters since. The position peaked at $944K in Q4 2017. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Kaizen Advisory held 610 shares of Alexion Pharmaceuticals worth $59K as of Q4 2018.
Kaizen Advisory bought 111 Alexion Pharmaceuticals shares in Q4 2018, an estimated $13.1K.
Alexion Pharmaceuticals made up 0.04% of Kaizen Advisory's portfolio in Q4 2018, its #304 holding.
Kaizen Advisory first reported a position in Alexion Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
Kaizen Advisory's Alexion Pharmaceuticals position peaked at $944K in Q4 2017.
608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Kaizen Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.